This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    IMC-F106C-101
Previous Study | Return to List | Next Study

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04262466
Recruitment Status : Recruiting
First Posted : February 10, 2020
Last Update Posted : September 28, 2023
Sponsor:
Information provided by (Responsible Party):
Immunocore Ltd

Brief Summary:
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME

Condition or disease Intervention/treatment Phase
Select Advanced Solid Tumors Drug: IMC-F106C Drug: IMC-F106C and atezolizumab and pembrolizumab Drug: IMC-F106C and chemotherapy Drug: IMC-F106C and tebentafusp Phase 1 Phase 2

Detailed Description:

The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases.

  1. Phase 1: To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 dose (RP2D) of IMC-F106C as a single agent and administered in combination with a checkpoint Inhibitor, chemotherapy, or another ImmTAC molecule.
  2. Phase 2: To assess the efficacy of IMC-F106C as a single agent in selected advanced solid tumors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Actual Study Start Date : February 25, 2020
Estimated Primary Completion Date : February 2024
Estimated Study Completion Date : February 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: IMC-F106C - Arm A - Phase 1 and Phase 2
Phase 1 dose escalation and Phase 2 monotherapy dose expansion
Drug: IMC-F106C
IMC-F106C weekly IV infusions or SC injections

Experimental: IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1
Dose Escalation
Drug: IMC-F106C and atezolizumab and pembrolizumab
IMC-F106C weekly IV infusions and atezolizumab Q3W IV infusion and pembrolizumab Q6W IV infusion

Experimental: IMC-F106C and chemotherapy - Arm C - Phase 1
Dose Escalation
Drug: IMC-F106C and chemotherapy
IMC-F106C weekly IV infusions and chemotherapy Q1-3W IV infusion

Experimental: IMC-F106C and another ImmTAC - Arm D - Phase 1
Dose Escalation
Drug: IMC-F106C and tebentafusp
IMC-F106C weekly IV infusions and tebentafusp weekly IV infusions




Primary Outcome Measures :
  1. Phase 1: Incidence of Dose-limiting toxicity (DLT)s [ Time Frame: From first dose to DLT period (28 days) ]
  2. Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE) [ Time Frame: from first dose to 30 days after the last dose ]
  3. Phase 1: changes in laboratory parameters [ Time Frame: from first dose to 30 days after the last dose ]
    Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities

  4. Phase 1: changes in vital signs [ Time Frame: from first dose to 30 days after the last dose ]
    Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities

  5. Phase 1: changes in electrocardiogram parameters [ Time Frame: from first dose to 30 days after the last dose ]
    QTcF interval absolute values and changes from baseline will be summarized

  6. Phase 1: dose interruptions, reductions, and discontinuations [ Time Frame: from first dose through last dose (anticipated for up to 12 months) ]
    Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to adverse event Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to treatment-related adverse event

  7. Phase 2: Best overall response (BOR) [ Time Frame: from first dose to approximately 2 years ]

Secondary Outcome Measures :
  1. Phase I: Best Overall Response (BOR) [ Time Frame: from first dose to approximately 2 years ]
  2. Progression-free survival (PFS) [ Time Frame: from first dose to approximately 2 years ]
  3. Duration of response (DOR) [ Time Frame: from first dose to approximately 2 years ]
  4. Overall survival [ Time Frame: from first dose to approximately 2 years ]
  5. Pharmacokinetics Area under the plasma concentration-time curve (AUC) [ Time Frame: approximately 3 weeks (IMC-F106C AUC will be assessed for ~3 weeks) ]
  6. Pharmacokinetics The maximum observed plasma drug concentration (Cmax) [ Time Frame: approximately 3 weeks (IMC-F106C Cmax will be assessed for ~3 weeks) ]
  7. Pharmacokinetics The time to reach maximum plasma concentration (Tmax) [ Time Frame: approximately 3 weeks (IMC-F106C Tmax will be assessed for ~3 weeks) ]
  8. Pharmacokinetics The elimination half-life (t1/2) [ Time Frame: approximately 3 weeks (IMC-F106C t1/2 will be assessed for ~ 3 weeks) ]
  9. Incidence of anti-IMC-F106C antibody formation [ Time Frame: approximately 2 years ]
  10. Changes in lymphocyte counts over time [ Time Frame: approximately 3 weeks ]
  11. Changes in serum cytokines over time [ Time Frame: approximately 3 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ECOG PS 0 or 1
  2. HLA-A*02:01 positive
  3. PRAME positive tumor
  4. Relapsed from, refractory to, or intolerant of standard therapy
  5. If applicable, must agree to use highly effective contraception
  6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol

Exclusion Criteria:

  1. Symptomatic or untreated central nervous system metastasis
  2. Recent bowel obstruction
  3. Ascites requiring recurrent paracentesis
  4. Significant immune-mediated adverse event with prior immunotherapy (patients in checkpoint inhibitor combination treatment)
  5. Inadequate washout from prior anticancer therapy
  6. Significant ongoing toxicity from prior anticancer treatment
  7. Out-of-range laboratory values
  8. Clinically significant lung, heart, or autoimmune disease
  9. Ongoing requirement for immunosuppressive treatment
  10. Prior solid organ or bone marrow transplant
  11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  12. Known history of human immunodeficiency virus (HIV)
  13. Significant secondary malignancy
  14. Hypersensitivity to study drug or excipients
  15. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention
  16. Pregnant or lactating
  17. Any other contraindication for applicable combination partner based on local prescribing information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04262466


Contacts
Layout table for location contacts
Contact: Clinical Lead +00 800-74451111 clinicaltrials@immunocore.com

Locations
Show Show 33 study locations
Sponsors and Collaborators
Immunocore Ltd
Layout table for additonal information
Responsible Party: Immunocore Ltd
ClinicalTrials.gov Identifier: NCT04262466    
Other Study ID Numbers: IMC-F106C-101
First Posted: February 10, 2020    Key Record Dates
Last Update Posted: September 28, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Immunocore Ltd:
ImmTAC
Immunotherapy
Bispecific T cell receptor fusion protein
Immune mobilizing monoclonal T cell receptor against cancer
Checkpoint inhibitor
PD1 / PD-1
PD-L1 / PDL1
Melanoma
Lung Cancer
Ovarian Cancer
Endometrial Cancer
Triple Negative Breast Cancer
NSCLC
Additional relevant MeSH terms:
Layout table for MeSH terms
Pembrolizumab
Atezolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action